IMUNON Advances IMNN-001 Phase 2 After Favorable Safety Review
LAWRENCEVILLE, N.J. — September 22, 2026 IMUNON announced that the Independent Data Monitoring Committee (IDMC) overseeing its Phase 2...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
LAWRENCEVILLE, N.J. — September 22, 2026 IMUNON announced that the Independent Data Monitoring Committee (IDMC) overseeing its Phase 2...
LAWRENCEVILLE, N.J. — September 10, 2026 IMUNON, Inc. announced a Cooperative Research and Development Agreement (CRADA) with the National...
